We have three newly approved meds for dementia. Brexpiprazole (Rexulti) for agitation, and donanemab (Kisunla) and lecanemab (Leqembi) for the core features of Alzheimer’s. Dr. Collier explains why none of these are first-line.

We have 30 stimulant formulations, but do all deserve prizes? We find a few with niche advantages, and three that rise to the top.

Sometimes we have a window of opportunity to make a difference. In this series we discuss time-frames where panic, clozapine, and metformin have the greatest benefits.

Sometimes we have a window of opportunity to make a difference. In this series we discuss time-frames where lithium, clozapine, and metformin have the greatest benefits.

Sometimes we have a window of opportunity to make a difference. Here, we discuss time-frames where lithium, clozapine, and metformin have the greatest benefits.

Learn how your patient’s life story can unlock psychotherapeutic avenues of treatment on our interview with Margaret Chisolm.